Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [ 177 Lu]Lu-DOTATATE.

Javian C MalcolmNadia FalzoneJennifer E GainsMatthew D AldridgeDavid MirandoBoon Q LeeMark N GazeKatherine A Vallis

Published in: EJNMMI physics (2022)

Lu]Lu-DOTATATE treatment for NBL. NBL is deemed a radiation sensitive tumour; therefore, dose-adaptive treatment planning schemes may be appropriate for some patients to compensate for decreasing tumour uptake as treatment progresses. Trial registration ISRCTN ISRCTN98918118. Registered 20 December 2013 (retrospectively registered).

Keyphrases

end stage renal disease
pet ct
clinical trial
chronic kidney disease
ejection fraction
newly diagnosed
study protocol
randomized controlled trial
peritoneal dialysis
neuroendocrine tumors
open label
phase iii
replacement therapy